ORGS - Orgenesis Inc Stock Price, Fair Value and News

$1.32-0.08 (-5.71%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ORGS Price Action

Last 7 days

29.4%

Last 30 days

21.1%

Last 90 days

-74.6%

Trailing 12 Months

-71.3%

ORGS RSI Chart

ORGS Valuation

Market Cap

6.8M

Price/Earnings (Trailing)

-0.1

Price/Sales (Trailing)

7.59

EV/EBITDA

-0.33

Price/Free Cashflow

-0.43

ORGS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ORGS Fundamentals

ORGS Revenue

Revenue (TTM)

899.0K

Rev. Growth (Yr)

215.45%

Rev. Growth (Qtr)

41.06%

ORGS Earnings

Earnings (TTM)

-55.4M

Earnings Growth (Yr)

-144.83%

Earnings Growth (Qtr)

-2.43%

ORGS Profitability

Operating Margin

-97.66%

EBT Margin

-3931.92%

Return on Equity

231.36%

Return on Assets

-186.48%

Free Cashflow Yield

-230.72%

ORGS Investor Care

Shares Dilution (1Y)

62.16%

Diluted EPS (TTM)

17.17

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	529.0K	662.0K	899.0K	0
2023	27.2M	18.3M	9.4M	530.0K
2022	35.6M	35.8M	35.9M	36.0M
2021	31.5M	32.8M	34.2M	35.5M
2020	32.5M	31.7M	30.9M	30.1M
2019	23.5M	26.0M	28.4M	33.3M
2018	13.5M	15.2M	16.9M	18.7M
2017	7.9M	8.6M	9.4M	10.1M
2016	3.7M	4.3M	5.0M	6.4M
2015	0	1.8M	2.4M	3.0M
2011	0	0	596.8K	1.2M
2010	0	0	0	2.5K

Get all data in R, Python etc through our Historical Stock Data APIs

About Orgenesis Inc

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

CEO	Ms. Vered Caplan M.Sc.
WEBSITE	orgenesis.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	167

Orgenesis Inc Frequently Asked Questions

What is the ticker symbol for Orgenesis Inc? What does ORGS stand for in stocks?

ORGS is the stock ticker symbol of Orgenesis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Orgenesis Inc (ORGS)?

As of Fri Dec 20 2024, market cap of Orgenesis Inc is 6.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ORGS stock?

You can check ORGS's fair value in chart for subscribers.

Is Orgenesis Inc a good stock to buy?

The fair value guage provides a quick view whether ORGS is over valued or under valued. Whether Orgenesis Inc is cheap or expensive depends on the assumptions which impact Orgenesis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORGS.

What is Orgenesis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, ORGS's PE ratio (Price to Earnings) is -0.1 and Price to Sales (PS) ratio is 7.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORGS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Orgenesis Inc's stock?

In the past 10 years, Orgenesis Inc has provided -0.312 (multiply by 100 for percentage) rate of return.